TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07815665: A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Sponsor: Summit Therapeutics · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 800 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT07815665 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07815665 Rescue Dossier →